Stock ANIK ANIKA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Anika Therapeutics, Inc.

Equities

ANIK

US0352551081

Market Closed - Nasdaq
Other stock markets
 21:00:00 01/05/2024 BST 		5-day change 1st Jan Change
26.49 USD +2.32% Intraday chart for Anika Therapeutics, Inc. +2.28% +16.90%
03-14 Barrington Ups Price Target on Anika Therapeutics to $37 From $29, Keeps Outperform Rating MT
03-13 Transcript : Anika Therapeutics, Inc., Q4 2023 Earnings Call, Mar 13, 2024

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Anika Therapeutics Swings to Q4 Earnings As Revenue Rises; to Cut 9% Workforce
Anika Therapeutics, Inc. Provides Earnings Guidance for the Fiscal Year 2024
Anika Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Anika Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Activist investor Caligan discloses 9.7% stake in Anika, nominates two director candidates
Anika Therapeutics, Inc. Announces Board Changes
Anika Therapeutics Says Surgeries Using Integrity Implant System Successful
Anika Therapeutics, Inc. Announces First Surgeries Performed Using the Integrity Implant System
Anika Therapeutics, Inc. Revises Revenue Guidance for the Fiscal Year 2023
Anika Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Anika Therapeutics, Inc. Announces the Full Market Release of the Revomotion Reverse Shoulder Arthroplasty System
Anika Therapeutics, Inc. Receives 510(k) Clearance for Integrity? Implant System, a Regenerative Hyaluronic Acid-Based Patch System for Augmentation of Rotator Cuff Repairs
Anika Therapeutics, Inc. Revises Revenue Guidance for the Fiscal Year 2023
Anika Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Anika Therapeutics, Inc. Appoints Anne Nunes as Senior Vice President, Chief Operations Officer
Anika Therapeutics, Inc. announces Completed Enrollment of the Pivotal Phase III Clinical Study for Hyalofast (Hyalofast 15-01) on Its Path to Achieving FDA Approval in the United States
Anika Therapeutics, Inc. Provides Earnings Guidance for the Year 2023
Anika Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Anika Therapeutics, Inc. announces an Equity Buyback for $20 million worth of its shares.
Anika Therapeutics, Inc. Appoints Gary Fischetti as Class III Director
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ANIK Stock
  4. News Anika Therapeutics, Inc.
  5. Other languages